Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.
Jonathan A. Chatzkel, MD
Advertisement
Articles by Jonathan A. Chatzkel, MD
Jonathan A. Chatzkel, MD, discusses the future treatment options in bladder cancer.
Jonathan A. Chatzkel, MD, discusses the emergence of novel therapies in relapsed/refractory locally advanced or metastatic urothelial cancer.
Advertisement
Latest Updated Articles
Dr. Chatzkel on the Emergence of Novel Therapies in Metastatic Urothelial CancerPublished: October 6th 2021 | Updated:
Dr. Chatzkel on Future Treatment Options in Bladder CancerPublished: February 17th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5